systhiperСистемные гипертензииSystemic Hypertension2075-082X2542-2189LLC «ИнтерМедсервис»systhiper-353Research ArticleОБЗОРЫЭффективность зофеноприла‌‌ при сердечно-сосудистых заболеванияхThe effectiveness of zofenopril in patients with cardiovascular diseaseКукесВ. Г.KukesV. G.noemail@neicon.ruАникинГ. С.AnikinG. S.noemail@neicon.ruГБОУ ВПО Первый Московский государственный медицинский университет им. И.М.Сеченова Минздрава РоссииРоссияГБОУ ВПО Первый Московский государственный медицинский университет им. И.М.Сеченова Минздрава России; ФГБУ Поликлиника №3 Управления делами Президента Российской Федерации, МоскваРоссия2014231220221125962Copyright © Кукес В.Г., Аникин Г.С., 20222022Кукес В.Г., Аникин Г.С.Kukes V.G., Anikin G.S.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.syst-hypertension.ru/jour/article/view/353

Гиперактивность ренин-ангиотензин-альдостероновой системы играет важную роль в патогенезе любой сердечно-сосудистой патологии. Среди множества средств, влияющих на активность ренин-ангиотензин-альдостероновой системы, ингибиторы ангиотензинпревращающего фермента являются самыми изученными препаратами, обладающими широким спектром благоприятных эффектов. Наличие сульфгидрильной группы в молекуле ингибитора ангиотензинпревращающего фермента зофеноприла обусловливает ряд уникальных свойств данного препарата. Последние данные свидетельствуют о его эффективности при лечении сочетанной сердечно-сосудистой патологии. В статье представлены последние данные исследований, посвященных эффективности и безопасности зофеноприла.

Hyperactivity of the renin-angiotensin-aldosterone system plays an important role in the pathogenesis of any cardiovascular disease. Angiotensin - converting enzyme inhibitors are the main drugs among many medicines influencing the activity of the renin-angiotensin-aldosterone system, and these inhibitors have a wide range of beneficial effects. The presence of the sulfhydryl group in a molecule of angiotensin-converting enzyme inhibitor (zofenopril) determines the number of unique properties of this drug. Recent results have been showing the effectiveness of treatment in case of combined cardiovascular disease. This article presents the results of the studies showing the efficacy and safety of zofenopril.

ренин-ангиотензин-альдостероновая системаингибиторы ангиотензинпревращающего ферментазофеноприлthe renin-angiotensin-aldosteronesystemangiotensin-converting enzyme inhibitorszofenoprilReferencesLaragh J.H, Brenner B.M. Hypertension: Pathophysiology, diagnosis, management. NY: Raven Press, 1995.Laragh J.H, Brenner B.M. Hypertension: Pathophysiology, diagnosis, management. NY: Raven Press, 1995.Persson S. Update on the use of angiotensin converting enzyme inhibitors and calcium antagonists in postinfarction patients.J Hypertens (Suppl.) 1995; 13 (2): S57-63.Persson S. Update on the use of angiotensin converting enzyme inhibitors and calcium antagonists in postinfarction patients.J Hypertens (Suppl.) 1995; 13 (2): S57-63.De Graeff P.A, van Gilst W.H. The effect of bradykinin on coronary flow and its potentiation by SH-containing ACE-inhibitors. Agents Actions (Suppl.) 1992; 38 (Pt 3): 110-8.De Graeff P.A, van Gilst W.H. The effect of bradykinin on coronary flow and its potentiation by SH-containing ACE-inhibitors. Agents Actions (Suppl.) 1992; 38 (Pt 3): 110-8.Диагностика и лечение артериальной гипертензии. Российские рекомендации (четвертый пересмотр) ВНОК. 2010.Диагностика и лечение артериальной гипертензии. Российские рекомендации (четвертый пересмотр) ВНОК. 2010.Napoli C, Bruzzese G, Ignarro L.J et al. Long - term treatment with sulfhydryl angiotensin - converting enzyme inhibition reduces carotid intima - media thickening and improves the nitric oxide/oxidative stress pathways in newly diagnosed patients with mild to moderate primary hypertension. Am Heart J 2008; 156 (6): 1154.e1-8.Napoli C, Bruzzese G, Ignarro L.J et al. Long - term treatment with sulfhydryl angiotensin - converting enzyme inhibition reduces carotid intima - media thickening and improves the nitric oxide/oxidative stress pathways in newly diagnosed patients with mild to moderate primary hypertension. Am Heart J 2008; 156 (6): 1154.e1-8.Borghi C, Ambrosioni E, Novo S et al. Comparison between zofenopril and ramipril in combination with acetylsalicylic acid in patients with left ventricular systolic dysfunction after acute myocardial infarction: results of a randomized, double - blind, parallel - group, multicenter, European study (SMILE-4). Clin Cardiol 2012; 35 (7): 416-23Borghi C, Ambrosioni E, Novo S et al. Comparison between zofenopril and ramipril in combination with acetylsalicylic acid in patients with left ventricular systolic dysfunction after acute myocardial infarction: results of a randomized, double - blind, parallel - group, multicenter, European study (SMILE-4). Clin Cardiol 2012; 35 (7): 416-23Borghi C, Ambrosioni E, Omboni S et al. Zofenopril and ramipril and acetylsalicylic acid in postmyocardial infarction patients with left ventricular systolic dysfunction: a retrospective analysis in hypertensive patients of the SMILE-4 study. J Hypertens 2013; 31 (6): 1256-64.Borghi C, Ambrosioni E, Omboni S et al. Zofenopril and ramipril and acetylsalicylic acid in postmyocardial infarction patients with left ventricular systolic dysfunction: a retrospective analysis in hypertensive patients of the SMILE-4 study. J Hypertens 2013; 31 (6): 1256-64.Borghi C, Ambrosioni E. Survival of Myocardial Infarction Long - term Evaluation Study Group. Effects of zofenopril on myocardial ischemia in post - myocardial infarction patients with preserved left ventricular function: the Survival of Myocardial Infarction Long - term Evaluation (SMILE)-ISCHEMIA study. Am Heart J 2007; 153 (3): 445.e7-14.Borghi C, Ambrosioni E. Survival of Myocardial Infarction Long - term Evaluation Study Group. Effects of zofenopril on myocardial ischemia in post - myocardial infarction patients with preserved left ventricular function: the Survival of Myocardial Infarction Long - term Evaluation (SMILE)-ISCHEMIA study. Am Heart J 2007; 153 (3): 445.e7-14.Narkiewicz K. Comparison of home and office blood pressure in hypertensive patients treated with zofenopril or losartan. Blood Press (Suppl.) 2007; 2: 7-12.Narkiewicz K. Comparison of home and office blood pressure in hypertensive patients treated with zofenopril or losartan. Blood Press (Suppl.) 2007; 2: 7-12.Farsang C. Blood pressure control and response rates with zofenopril compared with amlodipine in hypertensive patients. Blood Press (Suppl.) 2007; 2: 19-24.Farsang C. Blood pressure control and response rates with zofenopril compared with amlodipine in hypertensive patients. Blood Press (Suppl.) 2007; 2: 19-24.Nilsson P. Antihypertensive efficacy of zofenopril compared with atenolol in patients with mild to moderate hypertension. Blood Press (Suppl.) 2007; 2: 25-30.Nilsson P. Antihypertensive efficacy of zofenopril compared with atenolol in patients with mild to moderate hypertension. Blood Press (Suppl.) 2007; 2: 25-30.Malacco E, Castiglioni G, Corradi L et al. Dose-Response Relationship of Zofenopril in Essential Hypertension: A 24-Hour Blood Pressure-Monitoring Study. Clin Drag Invest 2002; 22 (1):9-15.Malacco E, Castiglioni G, Corradi L et al. Dose-Response Relationship of Zofenopril in Essential Hypertension: A 24-Hour Blood Pressure-Monitoring Study. Clin Drag Invest 2002; 22 (1):9-15.Borghi C, Cosentino E.R, Rinaldi E.R, Cicero A.F. Effect of zofenopril and ramipril on cardiovascular mortality in patients with chronic heart failure. Am J Cardiol 2013; 112 (1): 90-3.Borghi C, Cosentino E.R, Rinaldi E.R, Cicero A.F. Effect of zofenopril and ramipril on cardiovascular mortality in patients with chronic heart failure. Am J Cardiol 2013; 112 (1): 90-3.Malacco E, Omboni S. Antihypertensive efficacy of zofenopril plus hydrochlorothiazide fixed combination for treatment in metabolic syndrome. Adv Ther 2007; 24 (5): 1006-15.Malacco E, Omboni S. Antihypertensive efficacy of zofenopril plus hydrochlorothiazide fixed combination for treatment in metabolic syndrome. Adv Ther 2007; 24 (5): 1006-15.Agabiti-Rosei E, Manolis A, Zava D, Omboni S. Zofenopril Plus Hydrochlorothiazide and Irbesartan Plus Hydrochlorothiazide in Previously Treated and Uncontrolled Diabetic and Non - diabetic Essential Hypertensive Patients. Adv Ther 2014; 31 (2): 217-33.Agabiti-Rosei E, Manolis A, Zava D, Omboni S. Zofenopril Plus Hydrochlorothiazide and Irbesartan Plus Hydrochlorothiazide in Previously Treated and Uncontrolled Diabetic and Non - diabetic Essential Hypertensive Patients. Adv Ther 2014; 31 (2): 217-33.

The authors declare that there are no conflicts of interest present.